Biblio

Author Title [ Type(Desc)] Year
Filters: Author is Fuji, Shigeo  [Clear All Filters]
Journal Article
Fuji S, Kapp M, Einsele H. Alloreactivity of Virus-Specific T Cells: Possible Implication of Graft-Versus-Host Disease and Graft-Versus-Leukemia Effects. Front Immunol. 2013;4:330.
Ito R, Inamoto Y, Inoue Y, Ito A, Tanaka T, Fuji S, Okinaka K, Kurosawa S, Kim S-W, Yamashita T, et al. Characterization of late acute and chronic graft-versus-host disease according to the 2014 NIH consensus criteria in Japanese patients. Biol Blood Marrow Transplant. 2018.
Fuji S, Inoue Y, Makiyama J, Nakano N, Ito A, Kawakita T, Eto T, Suehiro Y, Itonaga H, Sawayama Y, et al. The clinical benefit of acute GVHD depends on the age at transplantation in patients with adult T-cell leukemia-lymphoma on behalf of the ATL Working Group of the Japan Society for Transplantation and Cellular Therapy. Bone Marrow Transplant. 2023.
Fuji S, Kida S, Morishima T, Nakata K, Miyashiro I, Ishikawa J. Clinical outcomes of patients with adult T-cell leukemia-lymphoma in a non-endemic metropolitan area: a retrospective analysis of the population-based Osaka Cancer Registry. Biol Blood Marrow Transplant. 2020.
Ohmoto A, Fuji S. Clinical status of induction therapy incorporating a hypomethylating agent for newly diagnosed adult acute myeloid leukemia compared to the standard 7+3 regimen. Expert Rev Hematol. 2023.
Harada K, Fuji S, Seo S, Uchida N, Kawakita T, Yano S, Ozawa Y, Yoshioka S, Onishi Y, Noguchi Y, et al. Comparison of immunosuppressant regimens in salvage cord blood transplantation for graft failure after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2020.
Tokunaga M, Nakano N, Fuji S, Wake A, Utsunomiya A, Ito A, Eto T, Kawakita T, Mori Y, Moriuchi Y, et al. Cord blood is a suitable donor source of allogeneic hematopoietic cell transplantation for adult T-cell leukemia-lymphoma: a nationwide retrospective study. Bone Marrow Transplant. 2023.
Tanaka T, Inamoto Y, Yamashita T, Fuji S, Okinaka K, Kurosawa S, Kim S-W, Tanosaki R, Fukuda T. Eltrombopag for treatment of thrombocytopenia after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2016.
Hashimoto H, Kitano S, Ueda R, Ito A, Tada K, Fuji S, Kim S-W, Yamashita T, Tomura D, Nukaya I, et al. Erratum to: Infusion of donor lymphocytes expressing the herpes simplex virus thymidine kinase suicide gene for recurrent hematologic malignancies after allogeneic hematopoietic stem cell transplantation. Int J Hematol. 2015.
Yuda S, Fuji S, Onishi A, Tanaka T, Inamoto Y, Kurosawa S, Kim S-W, Fukuda T. Extramedullary relapse of acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2019.
Kurosawa S, Yamaguchi T, Mori A, Tsukagoshi M, Okuda I, Ikeda M, Ueno T, Saito Y, Aihara Y, Matsuba Y, et al. Feasibility and usefulness of recommended screenings at long-term follow-up clinics for hematopoietic cell transplant survivors. Support Care Cancer. 2021.
Shinohara A, Oshima K, Fuji S, Umeda K, Kako S, Kurokawa M, Tsukada N, Kasai M, Kondo T, Hashii Y, et al. Hematopoietic stem cell transplantation in solid organ recipients with emphasis on transplant complications: a nationwide retrospective survey on behalf of the JSHCT, transplant complications working group. Biol Blood Marrow Transplant. 2019.
Fuji S, Byrne M, Nagler A, Mohty M, Savani BN. How we can mitigate the side effects associated with systemic glucocorticoid after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2021.
Kanda J, Ichinohe T, Fuji S, Maeda Y, Ohashi K, Fukuda T, Miyamura K, Iwato K, Eto T, Nakamae H, et al. The impact of HLA mismatch direction on the outcome of unrelated bone marrow transplantation: A retrospective analysis from the JSHCT. Biol Blood Marrow Transplant. 2014.
Fuji S, Sugita J, Najima Y, Konishi T, Tanaka T, Ohigashi H, Eto T, Nagafuji K, Hiramoto N, Matsuoka K-I, et al. Low- versus standard-dose post-transplant cyclophosphamide as GVHD prophylaxis for haploidentical transplantation. Br J Haematol. 2023.
Takenaka K, Fuji S, Matsukawa T, Uchida N, Kobayashi T, Tanaka M, Ara T, Ikegame K, Ozawa Y, Kanda Y, et al. Outcomes of allogeneic hematopoietic cell transplantation under letermovir prophylaxis for cytomegalovirus infection. Ann Hematol. 2023.
Yoshimitsu M, Fuji S, Utsunomiya A, Nakano N, Ito A, Ito Y, Miyamoto T, Suehiro Y, Kawakita T, Moriuchi Y, et al. Outcomes of allogeneic hematopoietic stem cell transplantation for ATL with HTLV-1 antibody positive donors: Allo-HCT for ATL from HTLV-1 antibody positive donors. Biol Blood Marrow Transplant. 2019.
Fuji S, Kapp M, Einsele H. Possible Implication of Bacterial Infection in Acute Graft-Versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation. Front Oncol. 2014;4:89.
Kurosawa S, Yamaguchi T, Mori A, Tsukagoshi M, Okuda I, Kayama M, Fuji S, Yamashita T, Ogawa C, Ito A, et al. Prognostic impact of pre-transplant quality of life and its post-transplant longitudinal change after allogeneic hematopoietic cell transplantation: a prospective study that administered SF-12 and EQ-5D. Transplant Cell Ther. 2021.
Onishi A, Fuji S, Kitano S, Maeshima AMiyagi, Tajima K, Yamaguchi J, Kawashima I, Kawajiri A, Takemura T, Ito A, et al. Prognostic implication of CTLA-4, PD-1, and PD-L1 expression in aggressive adult T-cell leukemia-lymphoma. Ann Hematol. 2022.
Fuji S, Ueno N, Hiramoto N, Asakura Y, Yakushijin K, Kamiyama Y, Kurosawa S, Kim S-W, Heike Y, Yamashita T, et al. Reduced-intensity conditioning regimen with low-dose ATG-F for unrelated bone marrow transplant is associated with lower non-relapse mortality than a regimen with low-dose TBI: a single-center retrospective analysis of 103 cases. Int J Hematol. 2013.
Cook LB, Fuji S, Hermine O, Bazarbachi A, Ramos JCarlos, Ratner L, Horwitz S, Fields P, Tanase A, Bumbea H, et al. Revised Adult T-Cell Leukemia-Lymphoma International Consensus Meeting Report. J Clin Oncol. 2019:JCO1800501.
Fuji S, Miyamura K, Kanda Y, Fukuda T, Kobayashi T, Ozawa Y, Iwato K, Uchida N, Eto T, Ashida T, et al. Short-term clinical outcomes after HLA 1-locus mismatched uPBSCT are similar to that after HLA-matched uPBSCT and uBMT. Int J Hematol. 2019.
Fuji S, Einsele H, Savani BN, Kapp M. Systematic nutritional support in allogeneic HSCT recipients. Biol Blood Marrow Transplant. 2015.
Watanabe M, Kanda J, Kojima H, Ikeda N, Fuji S, Kanda Y, Saji H, Tanaka H. Wide availability of HLA-matched or a few loci-mismatched donors in the graft-vs-host direction among non-sibling first-degree relatives. HLA. 2020.